Compare AbCellera Biologics Inc (ABCL) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs KB Financial Group, Inc. — how do they compare? AbCellera Biologics Inc trades at $8.95 (market cap $2.99B), while KB Financial Group, Inc. trades at $117.53 (market cap $41.21B). The key difference: KB Financial Group, Inc. is far larger — about 13.8× AbCellera Biologics Inc's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KB | |
|---|---|---|
Market Cap | $2.99B | $41.21B |
Sector | Health | Financials |
52-Week High | $9.76 | $124.01 |
52-Week Low | $2.78 | $77.50 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 2.67% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
